Recursion Secures FDA Alignment on Phase 3 Design for First-in-Class FAP Therapy

Recursion said the FDA agreed on a Phase 3 trial design for REC-4881 in FAP, a rare disease with no approved drugs.

Recursion Secures FDA Alignment on Phase 3 Design for First-in-Class FAP Therapy
Credit: Recursion Pharmaceuticals
Already have an account? Sign in.